Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:HCM NASDAQ:LNTH NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$71.05-3.6%$64.50$23.65▼$77.00$6.50B0.311.20 million shs1.41 million shsHCMHUTCHMED$10.79+0.7%$11.92$9.77▼$19.50$1.87B0.2653,588 shs106,811 shsLNTHLantheus$110.94+1.2%$96.93$47.25▼$111.86$7.13B-0.03963,570 shs913,593 shsPTCTPTC Therapeutics$81.57$72.95$43.17▼$87.50$6.77B0.562.30 million shs2.38 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-3.63%+8.09%+14.06%+6.38%+173.27%HCMHUTCHMED+0.75%+6.20%-5.76%-28.73%-28.31%LNTHLantheus+1.24%+4.63%+11.72%+46.55%+35.52%PTCTPTC Therapeutics0.00%-0.68%+10.45%+18.65%+67.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$71.05-3.6%$64.50$23.65▼$77.00$6.50B0.311.20 million shs1.41 million shsHCMHUTCHMED$10.79+0.7%$11.92$9.77▼$19.50$1.87B0.2653,588 shs106,811 shsLNTHLantheus$110.94+1.2%$96.93$47.25▼$111.86$7.13B-0.03963,570 shs913,593 shsPTCTPTC Therapeutics$81.57$72.95$43.17▼$87.50$6.77B0.562.30 million shs2.38 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-3.63%+8.09%+14.06%+6.38%+173.27%HCMHUTCHMED+0.75%+6.20%-5.76%-28.73%-28.31%LNTHLantheus+1.24%+4.63%+11.72%+46.55%+35.52%PTCTPTC Therapeutics0.00%-0.68%+10.45%+18.65%+67.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 2.71Moderate Buy$81.7315.03% UpsideHCMHUTCHMED 2.20Hold$16.8055.70% UpsideLNTHLantheus 2.73Moderate Buy$101.86-8.19% DownsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3612.00% UpsideCurrent Analyst Ratings BreakdownLatest HCM, LNTH, PTCT, and CGON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026HCMHUTCHMED Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.005/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/19/2026CGONCG Oncology Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/18/2026CGONCG Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.005/14/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.00 ➝ $82.005/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$4.04M1,551.14N/AN/A$9.33 per share7.62HCMHUTCHMED$548.51M3.43$2.72 per share3.97$7.17 per share1.50LNTHLantheus$1.54B4.69$6.47 per share17.16$16.43 per share6.75PTCTPTC Therapeutics$1.73B3.91$8.78 per share9.29($2.56) per share-31.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)HCMHUTCHMED$456.91MN/AN/A22.02N/AN/AN/AN/A8/3/2026 (Estimated)LNTHLantheus$233.56M$4.1526.7320.62N/A18.05%29.32%15.00%8/5/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A38.663.75-22.58%-362.45%-6.76%8/6/2026 (Estimated)Latest HCM, LNTH, PTCT, and CGON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A31.3031.25HCMHUTCHMED0.054.964.83LNTHLantheus0.472.832.64PTCTPTC TherapeuticsN/A2.442.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%HCMHUTCHMED8.82%LNTHLantheus99.06%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCGONCG Oncology4.80%HCMHUTCHMED3.60%LNTHLantheus1.70%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6188.20 million83.97 millionOptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableLNTHLantheus1,19365.11 million64.00 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableHCM, LNTH, PTCT, and CGON HeadlinesRecent News About These CompaniesInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $693,163.80 in StockJune 30 at 7:06 PM | marketbeat.comPictet Asset Management Holding SA Has $80.06 Million Stock Holdings in PTC Therapeutics, Inc. $PTCTJune 30 at 4:55 AM | marketbeat.comLouisiana State Employees Retirement System Takes Position in PTC Therapeutics, Inc. $PTCTJune 30 at 4:47 AM | marketbeat.comOP Asset Management Ltd Acquires Shares of 33,602 PTC Therapeutics, Inc. $PTCTJune 28 at 4:39 AM | marketbeat.comNeil Gregory Almstead Sells 20,960 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 28 at 4:37 AM | americanbankingnews.comNeil Gregory Almstead Sells 5,323 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 27, 2026 | insidertrades.comPTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 5,323 SharesJune 26, 2026 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Insider Sells 20,960 Shares of StockJune 26, 2026 | marketbeat.comNeil Gregory Almstead Sells 23,749 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 26, 2026 | americanbankingnews.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $1,921,294.10 in StockJune 25, 2026 | insidertrades.comPTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 10,462 SharesJune 23, 2026 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 19,686 SharesJune 23, 2026 | americanbankingnews.comMark Elliott Boulding Sells 10,462 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 23, 2026 | insidertrades.comPTC Therapeutics, Inc. $PTCT Shares Sold by BI Asset Management Fondsmaeglerselskab A SJune 23, 2026 | marketbeat.comMark Elliott Boulding Sells 10,462 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 22, 2026 | marketbeat.comPTC Therapeutics, Inc. $PTCT Shares Sold by Rockefeller Capital Management L.P.June 22, 2026 | marketbeat.comPacer Advisors Inc. Has $17.90 Million Position in PTC Therapeutics, Inc. $PTCTJune 21, 2026 | marketbeat.comPTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?June 18, 2026 | zacks.comIshara Investments LP Invests $2.74 Million in PTC Therapeutics, Inc. $PTCTJune 18, 2026 | marketbeat.comArmistice Capital LLC Sells 475,403 Shares of PTC Therapeutics, Inc. $PTCTJune 18, 2026 | marketbeat.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCM, LNTH, PTCT, and CGON Company DescriptionsCG Oncology NASDAQ:CGON$71.05 -2.68 (-3.63%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$70.00 -1.05 (-1.48%) As of 06/30/2026 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.HUTCHMED NASDAQ:HCM$10.79 +0.08 (+0.75%) Closing price 06/30/2026 03:58 PM EasternExtended Trading$10.76 -0.03 (-0.28%) As of 06/30/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Lantheus NASDAQ:LNTH$110.94 +1.36 (+1.24%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$111.28 +0.34 (+0.31%) As of 06/30/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.PTC Therapeutics NASDAQ:PTCT$81.57 0.00 (0.00%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$81.57 0.00 (0.00%) As of 06/30/2026 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
